Діагностичне Та Прогностичне Значення Кальпротектину (MRP8/MRP14) У Крові Хворих На Різні Варіанти Ювенільного Ідіопатичного Артриту

Boiko, Ya.

doi:10.22141/2224-0551.7.75.2016.86719

Cited by 1 publication

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the last years blood calprotectin (MRP8/14) has been extensively studied as a potential biomarker of disease activity and treatment response in rheumatic and other inflammatory diseases. A direct correlation was found between blood calprotectin level and JADAS 27 activity score, ESR and CRP in patients with JIA [ 14 ]. In patients with enthesitis-related arthritis a correlation was found between the MRP8/14 levels and disease activity [ 4 ].…”

Section: Discussionmentioning

confidence: 99%

“…The results of the study that we performed in the past have shown that blood calprotectin level was higher in patients with a systemic disease course (median 13,800 ng/ml) and statistically significantly differed from the parameters in healthy children (median 1,800 ng/ml), patients with articular forms of JIA (median 2,700 ng/ml),patients with polyarthritis with negative RF (median 3,800 ng/ml), and oligoarthritis (median 2,500 ng/ml). The highest calprotectin levels were found in patients with newly diagnosed sJIA, median being 32,500 ng/ml (from 13,800 to 177,000 ng/ml) [ 14 ]. The role of blood calprotectin (MRP8/14) for diagnostics of systemic JIA (sJIA) is confirmed by many studies; therefore blood calprotectin (MRP8/14) level is currently a widely recognized biomarker used to confirm the diagnosis of sJIA [ 15 , 16 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Blood calprotectin in children with juvenile idiopathic arthritis: relationship to flare development after discontinuation of treatment

Boyko

Ivanova²,

Vakaruk

et al. 2020

Reumatologia

View full text Add to dashboard Cite

Objectives The study aim was to prospectively evaluate the relationship between disease flare development in children with juvenile idiopathic arthritis (JIA) after discontinuation of treatment and serum calprotectin levels (MRP8/14). Material and methods Determination of blood serum level of calprotectin was performed in 54 patients with inactive JIA from various regions of Ukraine. The inclusion criterion was the existence of an inactive state of the disease in children with JIA for at least 6 months. During 1 week after blood sampling for determination of serum calprotectin (MRP8/14) level the patients were completely discontinued of all therapy. Determination of calprotectin level in blood serum was performed with reagents EK-MRP8/14 Buhlmann (MRP8/14; S100A8/9), Switzerland, using the ELISA method. Results The trial results showed that 3 months after discontinuation of treatment in patients with inactive JIA, the flares developed in 5 out of 54 patients (9.3%). The median calprotectin level before discontinuation of the treatment was 1,700 ng/ml in patients who developed a flare, and 1,500 ng/ml in other studied patients (not statistically significant). At 6 months, the flare had developed in an additional 3 out of 48 (6.3%) of patients, who continued to be followed up, while their median calprotectin serum levels were 1,300 ng/ml and 1,500 ng/ml respectively (not statistically significant). At 12 months, the flares had developed in 13 more out of 45 (28.9%) patients, who continued to be followed up, while the median calprotectin serum level in these patients before discontinuation of treatment was 1,100 ng/ml and 1,650 ng/ml respectively (not statistically significant). Conclusion After discontinuation of treatment a flare over the next year of follow-up developed in 38.9% of patients. The study results did not reveal a significant difference in calprotectin level in patients with JIA prior to complete discontinuation of treatment who developed a flare and those without a flare after 3, 6 and 12 months.

show abstract

Section: Discussionmentioning

confidence: 99%